Life sciences executive will lead world's preeminent diabetes research, clinical care and education organization

BOSTON - March 31, 2011 - Joslin Diabetes Center has appointed John L. Brooks III, a well-known leader in the life sciences industry, as President and Chief Executive Officer.

"Having seen John in action and worked closely with him, I know he will bring exceptional talents and experience to the role of Joslin chief executive," said Ralph James, interim Chairman of the Board of Trustees. "He has been a very successful senior executive and director in a number of life sciences firms, he is deeply committed to improving the lives of people with diabetes and he has played a major and highly productive role at Joslin since joining the Board in 2005."

Brooks became Chairman of Joslin's Board in May 2010. He will leave that role to take the chief executive position. He is replacing Kenneth E. Quickel, M.D., who retired as Joslin's President and CEO in October 2010. 

"I'm deeply honored and excited to take up the challenge as CEO at Joslin," said Brooks. "With the diabetes pandemic that is exploding across the world, Joslin's excellence in research, clinical care, education and awareness is even more essential than ever. We have never been more focused in advancing this institution so we can continue to provide the right solutions in all aspects of diabetes."

"Joslin has important initiatives underway in bringing our discoveries to market more quickly so that people with diabetes can benefit and our research will be more strongly supported," Brooks added. "We are operating very effectively and in a financially sound manner, and we are all fully engaged in every aspect of delivering our mission."

Following Dr. Quickel's retirement, Brooks has functioned as Joslin's acting chief executive, working with the Center's chief medical, scientific and financial officers.

Brooks has co-founded three life sciences companies including Insulet, which offers an insulin-pump system for people with type 1 diabetes. He has been principal of Healthcare Capital Consulting LLC, which advises early-stage life sciences companies, and a founder of Prism VentureWorks, which raised more than $1.25 billion in capital. Brooks also is chief executive of Reflectance Medical, which offers technology for non-invasive monitoring of critically ill patients. Before moving fully into his new role, Brooks will be transitioning out of his industry positions.

A native of Massachusetts, he holds an M.S. in Business and a B.B.A. cum laude from the University of Massachusetts at Amherst.

Ralph James, interim Chairman of the Board at Joslin, is Executive Director of External Relations at Harvard Business School. He has served on the Joslin Board since 2006. 

Related Articles

A Scientist working in lab
Type 1
Kidney Disease
Research Highlights

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

Three-year clinical trial finds reducing uric acid levels in type 1 diabetes provides no beneficial impact on the progression of diabetic kidney disease BOSTON – (November 8, 2019) – Diabetic kidney...
Read more on The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion
National Diabetes Month
Type 1
Type 2

National Diabetes Awareness Month

National Diabetes Awareness Month

Diabetes is growing at an epidemic rate in the United States and across the globe. According to the Centers for Disease Control and Prevention (CDC), over 30 million Americans have diabetes and 1.5...
Read more on National Diabetes Awareness Month
Red blood cell traveling in an artery
Type 1
Heart Disease
Research Highlights

Research may show way to minimize complications after heart treatment

Research may show way to minimize complications after heart treatment

BOSTON – (October 1, 2019) – People with diabetes are much more likely to develop heart disease than those without the condition. They also are several times more likely to develop complications after...
Read more on Research may show way to minimize complications after heart treatment